What is Retatrutide?
Retatrutide, previously identified during development as LY3437943, is an investigational peptide-based compound designed to activate GLP-1, GIP and glucagon receptors. For this reason it is commonly described in scientific literature as a triple hormone-receptor agonist.
How does Retatrutide work?
GLP-1, GIP and glucagon are involved in different aspects of metabolic signalling. Researchers investigate how simultaneously influencing these pathways affects energy balance, glucose-related signalling, appetite-related pathways and body composition.
What does human research show?
A 2023 Phase II randomised, double-blind, placebo-controlled study published in the New England Journal of Medicine enrolled 338 adults and followed participants for 48 weeks. That study provides genuine clinical evidence, while retatrutide remains an investigational clinical compound.
Evidence status
Cellular and mechanistic research is substantial. Animal research is substantial. Human clinical research includes substantial Phase II evidence.